WDFY2

Summary

WDFY2 (WD repeat and FYVE domain containing 2, HGNC:20482) is a protein-coding gene on chromosome 13q14.3, encoding WD repeat and FYVE domain-containing protein 2 (Q96P53). Acts in an adapter protein-like fashion to mediate the interaction between the kinase PRKCZ and its substrate VAMP2 and increases the PRKCZ-dependent phosphorylation of VAMP2.

This gene encodes a protein that contains two WD domains and an FYVE zinc finger region. The function of this gene is unknown. An alternatively spliced transcript variant of this gene may exist.

Source: NCBI Gene 115825 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 53 total
• MANE Select transcript: NM_052950

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20482
Approved symbol	WDFY2
Name	WD repeat and FYVE domain containing 2
Location	13q14.3
Locus type	gene with protein product
Status	Approved
Aliases	ZFYVE22
Ensembl gene	ENSG00000139668
Ensembl biotype	protein_coding
OMIM	610418
Entrez	115825

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 9 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000298125, ENST00000460145, ENST00000612477, ENST00000876143, ENST00000876144, ENST00000923031, ENST00000923032, ENST00000923033, ENST00000944287, ENST00000944288

RefSeq mRNA: 1 — MANE Select: NM_052950 NM_052950

CCDS: CCDS9429

Canonical transcript exons

ENST00000298125 — 12 exons

Exon	Start	End
ENSE00000939575	51660596	51660663
ENSE00000939576	51719198	51719348
ENSE00000939577	51727678	51727790
ENSE00000939578	51739049	51739175
ENSE00000939580	51755358	51755459
ENSE00000939581	51756332	51756462
ENSE00000995225	51703596	51703650
ENSE00000995227	51675170	51675243
ENSE00000995228	51758192	51758300
ENSE00001092625	51584462	51584824
ENSE00001476437	51759740	51767709
ENSE00003598440	51751310	51751415

Expression profiles

Bgee: expression breadth ubiquitous, 258 present calls, max score 97.21.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 25.7969 / max 956.8319, expressed in 1818 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
135199	14.3452	1803
135200	11.4517	1734

Top tissues by expression

260 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
upper arm skin	UBERON:0004263	97.21	gold quality
gingival epithelium	UBERON:0001949	94.95	gold quality
epithelial cell of pancreas	CL:0000083	94.56	silver quality
gingiva	UBERON:0001828	93.31	gold quality
endothelial cell	CL:0000115	93.27	gold quality
corpus callosum	UBERON:0002336	93.17	gold quality
nipple	UBERON:0002030	93.12	gold quality
skin of leg	UBERON:0001511	92.70	gold quality
kidney epithelium	UBERON:0004819	92.33	gold quality
tibia	UBERON:0000979	92.26	gold quality
body of pancreas	UBERON:0001150	92.26	gold quality
pancreatic ductal cell	CL:0002079	92.12	silver quality
monocyte	CL:0000576	91.88	gold quality
zone of skin	UBERON:0000014	91.77	gold quality
skin of abdomen	UBERON:0001416	91.77	gold quality
upper leg skin	UBERON:0004262	91.48	gold quality
oviduct epithelium	UBERON:0004804	91.28	gold quality
leukocyte	CL:0000738	91.11	gold quality
esophagus squamous epithelium	UBERON:0006920	90.14	gold quality
skin of hip	UBERON:0001554	89.99	gold quality
left ventricle myocardium	UBERON:0006566	89.67	silver quality
synovial joint	UBERON:0002217	89.41	gold quality
substantia nigra pars reticulata	UBERON:0001966	89.37	gold quality
inferior vagus X ganglion	UBERON:0005363	89.11	gold quality
lateral globus pallidus	UBERON:0002476	89.08	gold quality
adrenal tissue	UBERON:0018303	89.01	gold quality
layer of synovial tissue	UBERON:0007616	88.95	gold quality
subthalamic nucleus	UBERON:0001906	88.93	gold quality
sperm	CL:0000019	88.87	gold quality
calcaneal tendon	UBERON:0003701	88.73	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-119	yes	46.36
E-ANND-3	yes	6.95
E-CURD-135	no	748.05
E-MTAB-6379	no	301.81

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

95 targeting WDFY2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-4645-5P	99.98	65.81	1284
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-17-5P	99.89	73.83	2665
HSA-MIR-106B-5P	99.88	74.72	2795
HSA-MIR-20A-5P	99.88	74.76	2769
HSA-MIR-20B-5P	99.88	74.01	2621
HSA-MIR-519D-3P	99.88	73.97	2607
HSA-MIR-526B-3P	99.88	74.06	2587
HSA-MIR-93-5P	99.88	73.98	2606
HSA-MIR-1321	99.84	65.30	1811
HSA-MIR-4739	99.84	65.25	1832
HSA-MIR-4756-5P	99.84	64.98	1809
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-204-5P	99.79	71.62	2439
HSA-MIR-211-5P	99.79	71.65	2440
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-623	99.76	68.16	1170
HSA-MIR-4679	99.76	69.19	1229
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-4755-5P	99.71	70.34	2716

Literature-anchored findings (GeneRIF, showing 8)

• The ProF protein partially co-localizes with EEA1 on vesicular structures and binds to the protein kinases Akt and PKCzeta/lambda (protein kinase Czeta/lambda) via its WD-repeat propeller. (PMID:16792529)
• WDFY2, the WD40 and FYVE domain containing protein 2, has roles in endocytosis (PMID:16873553)
• presence of ProF increases the PKCzeta-dependent phosphorylation of VAMP2 in vitro (PMID:17313651)
• CDKN2D-WDFY2 fusion could be an important molecular signature for understanding and classifying sub-lineages among heterogeneous high-grade serous ovarian carcinomas. (PMID:24675677)
• Our results showed that WDFY2 inhibited cancer cell colony formation and migration via suppressing Akt pathway, making it a potential new therapeutic target in prostate cancer. (PMID:28653900)
• WDFY2 regulates exocytosis of MT1-MMP by controlling endosomal sorting of the v-SNARE VAMP3. (PMID:31253801)
• P63 modulates the expression of the WDFY2 gene which is implicated in cancer regulation and limb development. (PMID:31789342)
• Circ_0115118 regulates endometrial functions through the miR-138-1-3p/WDFY2 axis in patients with PCOSdagger. (PMID:36780172)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	wdfy2	ENSDARG00000040453
mus_musculus	Wdfy2	ENSMUSG00000014547
rattus_norvegicus	Wdfy2	ENSRNOG00000010042
drosophila_melanogaster	Stam	FBGN0027363
drosophila_melanogaster	Gga	FBGN0030141
drosophila_melanogaster	Wdfy2	FBGN0032246
caenorhabditis_elegans	stam-1	WBGENE00004109
caenorhabditis_elegans		WBGENE00008402

Paralogs (10): WDFY1 (ENSG00000085449), GGA1 (ENSG00000100083), TOM1 (ENSG00000100284), GGA2 (ENSG00000103365), STAM2 (ENSG00000115145), GGA3 (ENSG00000125447), STAM (ENSG00000136738), TOM1L1 (ENSG00000141198), TOM1L2 (ENSG00000175662), HGS (ENSG00000185359)

Protein

Protein identifiers

WD repeat and FYVE domain-containing protein 2 — Q96P53 (reviewed: Q96P53)

Alternative names: Propeller-FYVE protein, WD40- and FYVE domain-containing protein 2, Zinc finger FYVE domain-containing protein 22

All UniProt accessions (2): Q96P53, A0A087WZX3

UniProt curated annotations — full annotation on UniProt →

Function. Acts in an adapter protein-like fashion to mediate the interaction between the kinase PRKCZ and its substrate VAMP2 and increases the PRKCZ-dependent phosphorylation of VAMP2. Positively regulates adipocyte differentiation, by facilitating the phosphorylation and thus inactivation of the anti-adipogenetic transcription factor FOXO1 by the kinase AKT1. Plays a role in endosomal control of AKT2 signaling; required for insulin-stimulated AKT2 phosphorylation and glucose uptake and insulin-stimulated phosphorylation of AKT2 substrates. Participates in transferrin receptor endocytosis.

Subunit / interactions. Homodimer. Interacts (via WD repeats 1-3) with AKT1, AKT2, PRKCZ and PRKCI. Interacts with VAMP2. Forms a complex with VAMP2 and PRKCZ. Interacts with FOXO1. Forms a complex with AKT1 and FOXO1.

Subcellular location. Endosome. Early endosome. Cytoplasm.

Domain organisation. The FYVE-type zinc finger is essential for its vesicular localization.

RefSeq proteins (1): NP_443182* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000306	Znf_FYVE	Domain
IPR001680	WD40_rpt	Repeat
IPR011011	Znf_FYVE_PHD	Homologous_superfamily
IPR013083	Znf_RING/FYVE/PHD	Homologous_superfamily
IPR015943	WD40/YVTN_repeat-like_dom_sf	Homologous_superfamily
IPR017455	Znf_FYVE-rel	Domain
IPR019775	WD40_repeat_CS	Conserved_site
IPR020472	WD40_PAC1	Repeat
IPR036322	WD40_repeat_dom_sf	Homologous_superfamily
IPR042234	WDFY1/WDFY2	Family

Pfam: PF00400, PF01363

UniProt features (19 total): binding site 8, repeat 7, sequence conflict 2, chain 1, zinc finger region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96P53-F1	94.33	0.94

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (8): 290; 314; 317; 322; 325; 344; 347; 287

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 173 (showing top): GOBP_REGULATION_OF_FAT_CELL_DIFFERENTIATION, GOBP_REGULATION_OF_PHOSPHORYLATION, GOBP_POSITIVE_REGULATION_OF_FAT_CELL_DIFFERENTIATION, GOBP_POSITIVE_REGULATION_OF_CELL_DIFFERENTIATION, GOBP_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS, LIAO_METASTASIS, GOBP_FAT_CELL_DIFFERENTIATION, GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS, RIGGI_EWING_SARCOMA_PROGENITOR_UP, GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS, chr13q14, DURCHDEWALD_SKIN_CARCINOGENESIS_DN, GOBP_POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS, GOBP_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS, GOBP_REGULATION_OF_PROTEIN_METABOLIC_PROCESS

GO Biological Process (2): positive regulation of protein phosphorylation (GO:0001934), positive regulation of fat cell differentiation (GO:0045600)

GO Molecular Function (3): zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (4): early endosome (GO:0005769), vesicle (GO:0031982), cytoplasm (GO:0005737), endosome (GO:0005768)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of protein phosphorylation	1
protein phosphorylation	1
positive regulation of protein modification process	1
positive regulation of phosphorylation	1
fat cell differentiation	1
positive regulation of cell differentiation	1
regulation of fat cell differentiation	1
transition metal ion binding	1
binding	1
cation binding	1
endosome	1
membrane-bounded organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1
endomembrane system	1
cytoplasmic vesicle	1

Protein interactions and networks

STRING

1696 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
WDFY2	TFRC	P02786	687
WDFY2	WDFY4	Q6ZS81	578
WDFY2	AKT1	P31749	544
WDFY2	CATSPERZ	Q9NTU4	526
WDFY2	SERPINE3	A8MV23	510
WDFY2	TBC1D31	Q96DN5	488
WDFY2	CLDN15	P56746	485
WDFY2	CDC123	O75794	478
WDFY2	APPL1	Q9UKG1	470
WDFY2	SLC17A5	Q9NRA2	464
WDFY2	CMC2	Q9NRP2	440
WDFY2	CDKL1	Q00532	440
WDFY2	NOL10	Q9BSC4	438
WDFY2	EEA1	Q15075	437
WDFY2	CDKN2D	P55273	428

IntAct

22 interactions, top by confidence:

A	B	Type	Score
ARL6IP1	WDFY2	psi-mi:“MI:0915”(physical association)	0.560
WDFY2	RPRM	psi-mi:“MI:0915”(physical association)	0.560
YIF1A	WDFY2	psi-mi:“MI:0915”(physical association)	0.560
SYP	WDFY2	psi-mi:“MI:0915”(physical association)	0.560
WDFY2	NUDC	psi-mi:“MI:0915”(physical association)	0.560
DAP3	PNMA6A	psi-mi:“MI:0914”(association)	0.530
PNOC	CETN3	psi-mi:“MI:0914”(association)	0.530
WDFY2	U2SURP	psi-mi:“MI:0914”(association)	0.350
ATG16L1	ESYT2	psi-mi:“MI:0914”(association)	0.350
RBM17		psi-mi:“MI:0914”(association)	0.350
SLC7A3	ILVBL	psi-mi:“MI:0914”(association)	0.350
WDFY2	ARL6IP1	psi-mi:“MI:0915”(physical association)	0.000
WDFY2	YIF1A	psi-mi:“MI:0915”(physical association)	0.000
WDFY2	RPRM	psi-mi:“MI:0915”(physical association)	0.000
WDFY2	SYP	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (77): ERCC6L (Affinity Capture-MS), PALLD (Affinity Capture-MS), RBM17 (Affinity Capture-MS), RUFY1 (Affinity Capture-MS), RBM26 (Affinity Capture-MS), UTP6 (Affinity Capture-MS), GPD2 (Affinity Capture-MS), U2SURP (Affinity Capture-MS), MESDC2 (Affinity Capture-MS), NUP54 (Affinity Capture-MS), NFXL1 (Affinity Capture-MS), C2CD5 (Affinity Capture-MS), CHERP (Affinity Capture-MS), CCDC51 (Affinity Capture-MS), EFNB1 (Affinity Capture-MS)

ESM2 similar proteins: A0AUS0, A8XXC7, B3RQN1, B6K7R8, C5DF48, E9Q4P1, F4INY4, G5EEG7, O74453, O94394, P38123, P62883, P62884, Q18964, Q25306, Q2KIY3, Q2TAY7, Q2TBS9, Q38SD2, Q3EBD3, Q3MKM6, Q3UHC2, Q3UKJ7, Q5FVN8, Q5JTN6, Q5ZMC3, Q5ZME8, Q67UX0, Q6C953, Q6NRT3, Q6TNS2, Q76B40, Q7ZVA0, Q8BUB4, Q8H594, Q8IWB7, Q8N9V3, Q8SRB0, Q8W117, Q91WQ5

Diamond homologs: A0A0D1E015, A0JMD2, A1CEK1, A1DFP5, A2QWA2, A3LX75, A4QTV1, A4RF61, A8QCE4, A8XJZ8, B0WAQ0, B3MT31, B3P851, B4G2G5, B4IC49, B4JHI7, B4K982, B4M140, B4NFJ7, B4PRU6, E9Q4P1, O12940, O13821, O14964, O60784, O76902, O88746, P0CR78, P0CR79, P0CS26, P0CS27, P40343, P87157, Q0CJV3, Q0P4S0, Q0U4Z8, Q0V8S0, Q10410, Q13615, Q15075

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

53 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	43
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3391 predictions. Top by Δscore:

Variant	Effect	Δscore
13:51584824:GGT:G	donor_loss	1.0000
13:51584825:G:T	donor_loss	1.0000
13:51584826:T:G	donor_loss	1.0000
13:51675244:G:GG	donor_gain	1.0000
13:51703590:TTACA:T	acceptor_loss	1.0000
13:51703591:TACAG:T	acceptor_loss	1.0000
13:51703593:CA:C	acceptor_loss	1.0000
13:51703594:A:AG	acceptor_gain	1.0000
13:51703595:G:GG	acceptor_gain	1.0000
13:51703595:G:GT	acceptor_loss	1.0000
13:51703595:GGA:G	acceptor_gain	1.0000
13:51739176:G:GG	donor_gain	1.0000
13:51751308:A:AG	acceptor_gain	1.0000
13:51751309:G:GG	acceptor_gain	1.0000
13:51751309:GC:G	acceptor_gain	1.0000
13:51751412:GGAG:G	donor_gain	1.0000
13:51751413:GAGG:G	donor_gain	1.0000
13:51751414:AGGTA:A	donor_loss	1.0000
13:51751415:GGTA:G	donor_loss	1.0000
13:51751416:G:GA	donor_loss	1.0000
13:51755355:A:AG	acceptor_gain	1.0000
13:51755356:A:G	acceptor_gain	1.0000
13:51756458:GAAGA:G	donor_gain	1.0000
13:51756460:AGA:A	donor_gain	1.0000
13:51756461:GA:G	donor_gain	1.0000
13:51756461:GAG:G	donor_gain	1.0000
13:51756462:AG:A	donor_loss	1.0000
13:51756463:G:GG	donor_gain	1.0000
13:51756464:TAA:T	donor_loss	1.0000
13:51584825:G:GG	donor_gain	0.9900

AlphaMissense

2650 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
13:51739126:T:A	W226R	1.000
13:51739126:T:C	W226R	1.000
13:51739128:G:C	W226C	1.000
13:51739128:G:T	W226C	1.000
13:51751389:T:A	W269R	1.000
13:51751389:T:C	W269R	1.000
13:51755367:T:A	W281R	1.000
13:51755367:T:C	W281R	1.000
13:51755369:G:C	W281C	1.000
13:51755369:G:T	W281C	1.000
13:51755385:T:A	C287S	1.000
13:51755385:T:C	C287R	1.000
13:51755386:G:A	C287Y	1.000
13:51755386:G:C	C287S	1.000
13:51755387:C:G	C287W	1.000
13:51755406:T:C	F294L	1.000
13:51755408:C:A	F294L	1.000
13:51755408:C:G	F294L	1.000
13:51755412:T:A	W296R	1.000
13:51755412:T:C	W296R	1.000
13:51755414:G:C	W296C	1.000
13:51755414:G:T	W296C	1.000
13:51755455:G:C	R310T	1.000
13:51755456:A:C	R310S	1.000
13:51755456:A:T	R310S	1.000
13:51756332:C:G	H312D	1.000
13:51756335:C:G	H313D	1.000
13:51756337:C:A	H313Q	1.000
13:51756337:C:G	H313Q	1.000
13:51756338:T:A	C314S	1.000

dbSNP variants (sampled 300 via entrez): RS1000016727 (13:51625859 A>G), RS1000029056 (13:51672015 C>A), RS1000033571 (13:51653070 A>G), RS1000050857 (13:51695753 C>G,T), RS1000057081 (13:51685475 G>A,T), RS1000062895 (13:51679002 A>C), RS1000081347 (13:51608636 G>A,C), RS1000120137 (13:51586517 T>C), RS1000133711 (13:51658988 G>A,T), RS1000155429 (13:51614135 A>G), RS1000172116 (13:51752604 G>A,C), RS1000177014 (13:51754988 T>C), RS1000178189 (13:51717152 A>G), RS1000179457 (13:51703403 T>A), RS1000204621 (13:51753017 G>T)

Disease associations

OMIM: gene MIM:610418 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST009440_14	Age-related cognitive decline (attention/processing speed) (slope of z-scores)	4.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007710	cognitive decline measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, increases methylation	2
aristolochic acid I	decreases expression	1
alpha-pinene	affects cotreatment, decreases expression, increases abundance	1
bisphenol A	decreases methylation	1
methylparaben	increases expression	1
sodium arsenite	affects methylation	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
aflatoxin B2	decreases methylation	1
methacrylaldehyde	affects cotreatment, decreases expression, increases abundance	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
bisphenol S	decreases methylation	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Arsenic Trioxide	increases expression	1
Leflunomide	increases expression	1
Acetaminophen	increases expression	1
Acrolein	affects cotreatment, decreases expression, increases abundance	1
Air Pollutants	affects cotreatment, decreases expression, increases abundance	1
Arsenic	affects methylation	1
Calcitriol	increases expression, affects cotreatment	1
Diazinon	increases methylation	1
Hydrogen Peroxide	decreases expression	1
Ozone	affects cotreatment, decreases expression, increases abundance	1
Plant Extracts	affects cotreatment, increases expression	1
Testosterone	affects cotreatment, increases expression	1
Dronabinol	increases expression	1
1-Methyl-4-phenylpyridinium	increases expression	1
Cyclosporine	increases expression	1

Cellosaurus cell lines

7 cell lines: 7 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_3768	OV-90	Cancer cell line	Female
CVCL_4Z23	OV90C-A	Cancer cell line	Female
CVCL_4Z24	OV90C-D	Cancer cell line	Female
CVCL_4Z25	OV90D-6	Cancer cell line	Female
CVCL_4Z26	OV90D-7	Cancer cell line	Female
CVCL_4Z27	OV90P-3	Cancer cell line	Female
CVCL_4Z28	OV90P-7	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.